Next Article in Journal
Testing Adaptive Therapy Protocols Using Gemcitabine and Capecitabine in a Preclinical Model of Endocrine-Resistant Breast Cancer
Next Article in Special Issue
Unveiling Extramedullary Myeloma Immune Microenvironment: A Systematic Review
Previous Article in Journal
Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel
Previous Article in Special Issue
BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma
 
 
Due to scheduled maintenance work on our servers, there may be short service disruptions on this website between 11:00 and 12:00 CEST on March 28th.
Review

Article Versions Notes

Cancers 2024, 16(2), 256; https://doi.org/10.3390/cancers16020256
Action Date Notes Link
article html file updated 1 January 2026 23:59 CET Update https://www.mdpi.com/2072-6694/16/2/256/html
article html file updated 12 September 2025 10:56 CEST Update -
article html file updated 23 August 2025 02:39 CEST Update -
article html file updated 24 June 2025 07:35 CEST Update -
article html file updated 6 January 2024 08:39 CET Original file -
article pdf uploaded. 6 January 2024 08:37 CET Version of Record https://www.mdpi.com/2072-6694/16/2/256/pdf
article xml uploaded. 6 January 2024 08:37 CET Update https://www.mdpi.com/2072-6694/16/2/256/xml
article xml file uploaded 6 January 2024 08:37 CET Original file -
Back to TopTop